ArticleJournal of inflammation research2026
The Association Between C-Reactive Protein-to-Albumin Ratio and in-Hospital Mortality in Patients with
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The C-reactive protein-to-albumin ratio (CAR), integrating inflammation (CRP) and physiological reserve (albumin), shows promise as a prognostic biomarker in critical illness, but its specific role in Methods: Between 2019 and 2024, 264 adult patients with KP-BSI at a tertiary medical center were included in this retrospective cohort study. The primary endpoint was in-hospital mortality, Patients were categorized into three groups according to tertiles of the CAR: T1 < 3.91, T2 3.91-6.91, and T3 > 6.91. To assess the relationship between serum CAR levels and mortality risk, we applied multivariable Cox proportional hazards models and constructed Kaplan-Meier survival curves, with subgroup analyses incorporating interaction testing across sex, age, diabetes, septic shock, and CRKP status, as well as sensitivity analyses excluding patients with chronic liver disease, those with missing covariates, and including those with a length of hospital stay exceeding 180 days. The discriminatory performance of CAR was further assessed using receiver operating characteristic (ROC) curve analysis. Results: Among the 264 patients included in the final analysis, 121 (45.8%) died during hospitalization. Non-survivors showed significantly higher CAR (7.1 ± 3.4) than survivors (4.8 ± 3.0) (p<0.001). After adjusting for potential confounders, each unit increase in CAR was independently associated with a higher risk of in-hospital mortality (hazard ratio (HR)=1.12, 95% confidence interval (CI): 1.07-1.19, p<0.001). When treated as a categorical variable, compared to the reference group (T1 group), patients in the highest tertile (T3) had a substantially elevated mortality risk (HR=3.12, 95% CI: 1.83-5.34, P<0.001). Subgroup analyses and sensitivity analyses consistently supported the robustness of the results. The ROC analysis demonstrated that CAR had moderate discriminatory ability. Conclusion: CAR is independently associated with in-hospital mortality in patients with KP-BSI. This readily available biomarker offers meaningful early risk stratification and may help identify patients at elevated risk who could benefit from closer monitoring and targeted clinical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.